Indefinite Delivery Contract SPE2DR25D2018

The Indefinite Delivery Contract (IDC) SPE2DR25D2018 is a $999,999,999 single-award contract issued by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract's purpose is to provide a comprehensive range of pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits, to support military healthcare programs globally. This IDC serves as a primary vehicle for DLA to efficiently procure essential medical commodities across multiple therapeutic areas such as cardiovascular health, diabetes management, mental health, pain management, infectious disease prevention, and general medical care. The contract has a 30-month base period with three 30-month option periods, running through December 2036. This IDC is part of the DLA's broader Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which aims to establish multiple regional primary supplier contracts to enhance the Department of Defense's pharmaceutical supply chain resiliency.

The original federal contract opportunity, posted in February 2024, sought to solicit bids for the PPV-G GEN V program through an unrestricted, fully competitive acquisition. The DLA Troop Support Medical intends to make multiple regional primary supplier awards, with at least three different contractors selected, as well as a separate backup supplier contract. The contract will be a firm-fixed-price, requirements-type contract, with awards based on the lowest overall price considering distribution fees for brand/generic and specialty drugs. The total estimated value for all regions and options is $30.3 billion.